Economic Evaluation of Alzheimer.

Abstract

The Alzheimer diseases (AD) steadily increase with age in the early population. Considering that all over the world holds the fastest aging population. According to the Alzheimer’s Association, cost spending is projected to be $2000 billion in 2050. The purpose of this study is to observe the cost effectiveness analysis (CEA) for the Alzheimer Drug. The report was reviewed through report of ministry of welfare in Korea and clinical report data of paper about the Alzheimer drug inhibitors which are Aricept, Exelon and Reminyl. This analysis was used by CEA. In Korea, the patients increased 84,000 in 2005 and 262,000 in 2010. The patients increase 3.1 fold more increase. The total medical expenses $0.13 billion in 2005 and $0.81 billion in 2010. The total medical expense was 6.1 more increase. The per capita cost of treatment of Alzheimer diseases (AD) spends about 1.5$ in 2005 and 3.1$ in 2010. The per capita cost of treatment is 2 times greater. Also,The medical fee of Aricept is $2, Exelon is $1.8 and Reminyl $1.3 in Korea. The best drug of cost effectiveness is Reminyl and then Aricept. However, Exelon rejected within the cost effectiveness analysis, when anyone has a limited cost. This revision strived to reduce the per capita cost of treatment of AD. Most of all, it is critical not to delay care in Alzheimer patients in order to avoid increased direct medical costs. Therefore, in Alzheimer care, it is most critical to adequately check the symptom early discovery through the appropriate management techniques.